Date: 2012-03-13
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Vivalis (France) undisclosed European mid-sized biopharmaceutical company
Therapeutic area: undisclosed
Type agreement: licensing
Action mechanism:
Disease: undisclosed
Details: Vivalis has announced the signature of a joint collaboration and commercial license agreement related to the use of Vivalis EB66® cell line, for the setting up of an industrial process and the manufacturing of clinical batches of an antibody, proprietary of a European mid-sized biopharmaceutical company. Terms of the agreement were not disclosed.
Financial terms: Financial terms include upfront, milestones payments and royalties. Vivalis is also financed for the process development and the production of clinical batches.
Latest news:
